On March 25, AstraZeneca announced that the European Medicines Agency (EMA) officially approved its SGLT-2 inhibitor, Forxiga (Dalagide) as adjunctive therapy for insulin, for optimal use of optimal doses of insulin to control poor blood sugar. Type 1 diabetes patients (BMI ≥ 27). This is the first time that… Continue Reading SGLT-2 inhibitors first approved for the treatment of type 1 diabetes

  On March 4, Novartis published a clinical trial of a Phase III study of Cosentyx in the treatment of moderate to severe plaque psoriasis at the 2019 Annual Meeting of the American Academy of Dermatology (AAD2019). The reason for this study is that 441 of the 543 patients with… Continue Reading The third phase of clinical data of Cosynmyx China, a new psoriasis drug, was released for the first time: excellent efficacy and significant benefit

  On February 27th, Bayer announced its 2018 financial report. The Group achieved a total revenue of 39.586 billion euros, an increase of 13.1% compared with 2017. The total revenue of the pharmaceutical business was 16.746 billion euros (-0.6%), the income from consumer health business was 5.45 billion euros (-7%),… Continue Reading Bayer 2018 earnings report: Acarbose reverse growth! New drug development is broken, the structure is about to be adjusted

  Almost everyone did not notice that the cumulative market value of the three CRISPR listed companies tripled between June 2017 and June 2018, with a cumulative market value of nearly $6 billion. However, in the past six months, the market value of these three companies has fallen by nearly… Continue Reading Progress of the latest clinical trials of 3 CRISPR listed companies

  Clinical outcomes are one of the gold standards for assessing the availability of new drugs, which often determines their reputation after listing. As a “living drug”, CAR-T therapy is to collect blood from patients, transport blood samples to the production GMP center, extract and purify T cells, lentivirus transfection… Continue Reading CAR-T production, outsourcing or building your own factory?

  The original research pricing strategy caused controversy A few years ago, a group of oncologists wrote an editorial on drug prices, with the breakthrough tyrosine kinase inhibitor Gleevec (imatinib mesylate) as an example of extreme pricing practices. This has sparked a major discussion about the price and value of… Continue Reading Reflection on Gleevec pricing

  Last year, the FDA approved two CAR-T products to be marketed, namely Kymriah of Novartis and Yescarta of Gilead. Although both products are capable of targeting CD19, there are significant differences in their CAR design. The co-stimulation zone of Kymriah uses 4-1BB, while the co-stimulation zone of Yescarta’s CAR… Continue Reading Yescarta vs. Kymriah, which CAR-T product is better?

Trabexidine   In the late 1980s, Brian Bingham was still a Ph.D. He carries his bags to the Florida Keys every month. Among the mangroves that surround the island, there is the sea squirts that the marine biologist has been studying, and it is also the best place to study… Continue Reading Trabexidine: the first anti-tumor drug derived from the ocean

FDA approves first GPCR antibody drug! The first new drug for migraine prevention in 20 years, with a peak sales forecast of $12.5 billion. An article published by Nature Reviews Drug Discovery in July last year showed that the FDA approved a total of 475 G-protein coupled receptor (GPCR)-related targeted… Continue Reading FDA approves first GPCR antibody drug with a peak sales forecast of $12.5 billion

IDO Inhibitor Stops Recruiting Patients in Multiple Clinical Trials On May 2, Incyte announced that multiple late-stage clinical trials of epacadostat with MSD, Bristol-Myers Squibb, and Aslicon PD-1/PD-L1 drugs will stop the recruitment of patients. At the same time, Bristol-Myers Squibb also stopped several clinical trials with the PD-1 combination… Continue Reading A week of news